The QualityStocks Daily Tuesday, April 3rd, 2018

Today's Top 3 Investment Newsletters

MarketBeat (ENGT) +150.00%

MarketClub Analysis (CASI) +47.54%

InvestorPlace (INNT) +41.54%

The QualityStocks Daily Stock List

Orgenesis, Inc. (ORGS)

OTCPicks, Stock News Now, IRGnews Alert, SmallCapNetwork, Greenbackers, Streetwise Reports, and pastwellness reported earlier on Orgenesis, Inc. (ORGS), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Orgenesis, Inc. is a fully-integrated cell therapy and contract development and manufacturing company. It has a novel therapeutic technology for the treatment of diabetes. The OTCQB-listed Company has expertise and unique experience in cell therapy development and manufacturing. Orgenesis is headquartered in Germantown, Maryland.

Through its Israeli subsidiary, Orgenesis Ltd., Orgenesis is a pioneer in the development of technology designed to successfully reprogram human liver cells into glucose-responsive, fully functional, Insulin Producing Cells (IPCs).

Orgenesis also has a fully-owned subsidiary contract manufacturing and development company - MaSTherCell S.A. (Belgian subsidiary). This subsidiary’s commitment is to cell therapy for advanced medicinal products. MaSTherCell (a full-service contract development and manufacturing organization (CDMO)) specializes in the delivery of optimized process industrialization capacities to cell therapy organizations

Orgenesis has a novel therapeutic approach in the treatment of diabetes through correcting malfunctioning organs with new functional tissues created from the patient’s own existing organs. The Company uses a molecular and cellular approach directed at transforming liver cells into functional insulin-producing cells as a treatment for diabetes. The new therapeutic approach is called Autologous Insulin Producing (AIP) cell transplantation.

Orgenesis entered into several strategic partnerships and joint venture (JV) agreements in 2016. It entered into a JV Agreement with CureCell; it is collaborating in the contract development and manufacturing of cell therapy products in Korea.

Orgenesis Ltd, its Israeli subsidiary, entered into a pharma Cooperation and Project Funding Agreement (CPFA) with KORIL and CureCell. KORIL will provide funding for a joint research and development project for the use of AIP cells for the treatment of diabetes.

Additionally, Orgenesis entered into a JV agreement with Atvio Biotech Ltd., an Israeli company. This agreement is to collaborate in the contract development and manufacturing of cell and virus therapy products in the field of regenerative medicine.

In December, Orgenesis Ltd., the wholly-owned subsidiary of Orgenesis, Inc., announced that Orgenesis and Pall Corporation completed their joint development program supported by the Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation.  Orgenesis is centered on developing an innovative autologous cell-based therapy for the treatment of diabetes.

Pall Corporation provides advanced products and services to meet the demanding requirements of customers discovering, developing, and producing biologics, cell and gene therapies and classic pharmaceuticals. The BIRD Foundation works to encourage and facilitate cooperation between U.S. and Israeli companies in a broad array of technology sectors. BIRD offers funding to selected projects.

Yesterday, Orgenesis announced it entered into a non-binding licensing and supply agreement-in-principle with Humavox Ltd. and MirCod for the development of important technology related to biological sensing with wireless charging for Orgenesis’ clinical development and manufacturing projects. The parties expect to complete due diligence and execute a definitive agreement within 45 days.

Orgenesis, Inc. (ORGS), closed Tuesday's trading session at $10.31, up 3.32%, on 32,141 volume with 103 trades. The average volume for the last 60 days is 30,202 and the stock's 52-week low/high is $2.76/$16.80.

chart

Mikros Systems Corp. (MKRS)

Promotion Stock Secrets, Marketbeat, Fast Money Alerts, Actual Gains, AddictivePennyStocks, Chatter Box Stocks, StockLockandLoad, PennyStockRumors.net, OTCEquity, PennyStocks24, AwesomeStocks, Wall Street Mover, PricelessPennyStocks, StockRockandRoll, StockBomb., ResearchOTC, and OTPicks reported on Mikros Systems Corp. (MKRS), and we also report on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Mikros Systems Corp. is a provider of advanced maintenance and monitoring solutions for mission-critical systems. The Company is an advanced technology enterprise that designs and manufactures specialized electronic systems for the Department of Defense. Its main business is to pursue and obtain contracts from the Department of Homeland Security, the U.S. Navy, and other governmental authorities. Mikros Systems is based in Princeton, New Jersey, and has its Manufacturing and Depot Center in Largo, Florida.

Mikros Systems produces advanced maintenance systems for the Navy. These include the ADEPT Maintenance Automation Workstation and the ADSSS Condition Based Maintenance system for the Littoral Combat Ship. ADEPT systems are in use daily for performance optimization of advanced radar systems.

Mikros’ capabilities include technology management, electronic systems engineering and integration, radar systems engineering, command, control, communications, computers and intelligence systems engineering, and communications engineering.

The Company’s Lifecycle Support capability is centered on ensuring the systematic interactions between Integrated Logistics Support (ILS), Depot, and Field Support activities are integrated to accomplish the highest levels of system readiness. Mikros purchased certain software products, intellectual property (IP) and related assets from VSE Corp. The main software programs purchased by Mikros are the Prognostics Framework (PF) and Diagnostic Profiler (DP) programs.

The Diagnostic Profiler software is utilized internationally by numerous multinational companies for optimized maintenance of diverse product lines. In addition, Diagnostic Profiler is used by the U.S. Air Force for depot test programs.

Prognostics Framework is used by the U.S. Army for manifold missile defense systems. These software products provide Mikros Systems with the opportunity to service commercial customers and additional Department of Defense customers outside the Navy.

Yesterday, Mikros Systems announced financial results for 2017. Revenues for 2017 were $7,196,131 versus $5,067,365 in 2016. This represents an increase of $2,128,766, or 42 percent. Net Income grew 186 percent to $236,000 in 2017 versus $82,490 in 2016.

The Company’s Revenue increase was mainly because of production orders for 37 Adaptive Diagnostic Electronic Portable Testset (ADEPT) units in 2017 and the receipt of additional contract awards and task orders for engineering services, support, repairs and calibration services.

In 2017, Mikros Systems was awarded a $35.1 million multi-year indefinite delivery, indefinite quantity contract from the Naval Surface Warfare Center at Crane, IN for the delivery and support of the Company’s ADEPT product.

Mikros Systems’ Chief Executive Officer, Mr. Tom Meaney, stated, “We are pleased to report another strong year of financial performance for our shareholders.  We nearly tripled our profits, increased our revenues by over 40 percent, and generated new contract awards and task orders from the United States Department of Defense.

Mikros Systems Corp. (MKRS), closed Tuesday's trading session at $0.374, up 13.33%, on 9,200 volume with 10 trades. The average volume for the last 60 days is 15,649 and the stock's 52-week low/high is $0.3299/$0.63.

chart

True Nature Holding, Inc. (TNTY)

Real Pennies, MarketWatch, InvestorsHub, Marketwired, Stockhouse, and OTC Markets reported on True Nature Holding, Inc. (TNTY), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

True Nature Holding, Inc.’s business plan considers a roll-up of businesses in the compounding pharmacy industry. The plan contemplates manifold acquisitions of businesses that have conventionally operated locally, but that have specialty formulations that may have a larger market. The Company is targeting the acquisition of pharmacies that serve the human, and in some cases, pet markets. True Nature Holding has its corporate office in Atlanta, Georgia.

True Nature Holding’s focus is on the consolidation of the compound pharmacy industry. Its plan is to acquire a series of businesses that specialize in compounding pharmacy activities, primarily direct to consumers, and to doctors and veterinary professionals. Pharmaceutical compounding is performed in compounding pharmacies. It is the creation of a specific pharmaceutical product to fit the exclusive need of a patient.

The Company has acquired 100 percent of the membership interests of Newco4pharmacy, LLC. Newco4pharmacy is a development stage business targeted at establishing a network of compounding pharmacies.

True Nature is creating a blend of human and veterinary businesses, and a balance of cash oriented operations, and more usual insurance based operations. The Company expects to create three operating subsidiaries to hold its planned acquisitions, while maintaining its present holding company structure for the publicly held entity. The expectation is that all the new subsidiaries will be wholly-owned, single member LLC's, controlled and managed by the public company.

True Nature Holding’s intention is to establish a joint venture (JV) for-profit subsidiary; True Nature Community Health, Inc. This will be owned by the public company, and a newly formed not-for-profit entity; The True Nature Community Health Foundation. It is launching this new initiative targeted at supporting the need for lower cost pharmaceuticals within the medically underserved small town and rural marketplaces.

True Nature Holding is in the process of acquiring the newly formed subsidiary; True Nature Community Health, Inc. (Community Health Subsidiary). It will have an 80 percent ownership in the Community Health Subsidiary. The remaining 20 percent ownership will be held by not-for-profit organizations.

Last month, True Nature Holding released an update to its shareholders on its strategy. This includes potential acquisitions, financing prospects, and its position concerning plans to participate in the Cryptocurrency and Blockchain space.

Regarding acquisitions, Dr. Jordan Balencic, Chairman, and interim Chief Executive Officer, said, "First, in alignment with our current business model, we have three near-term acquisition prospects at this time. The smallest is an asset acquisition involving the operating assets of a compounding pharmacy operation near West Palm Beach, Florida… Secondly, we have had some discussions with a group of investors who hold interests in a set of clinics, diagnostic facilities, and pharmacies, generally in Florida, mostly in the Dade and Broward county markets.”

Dr. Balencic continued, "We have continued conversations with other pharmacy operators with whom we have had long-term relationships, and subject to terms and financing, could move on those in early 2018 as well as the others previously mentioned.

True Nature Holding, Inc. (TNTY), closed Tuesday's trading session at $0.0988, up 12.27%, on 40,817 volume with 9 trades. The average volume for the last 60 days is 23,418 and the stock's 52-week low/high is $0.0418/$0.6799.

chart

Cotinga Pharmaceuticals, Inc. (COTQF)

Stockhouse, InvestorsHub, MarketWatch, YCharts, NetworkNewsWire, and Penny Stock Hub reported on Cotinga Pharmaceuticals, Inc. (COTQF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Cotinga Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer. The Company uses proprietary artificial intelligence (AI) technologies to pursue a targeted and transformational approach to treating cancer and other unmet medical needs. The Company’s drug candidates have demonstrated the ability to target key pathways and prevent cancer cells from thriving and replicating.

Established in 1999, Cotinga Pharmaceuticals has offices in Boston, Massachusetts and London, Ontario. The Company previously went by the name Critical Outcome Technologies, Inc. It changed its name to Cotinga Pharmaceuticals, Inc. this past January.

The intention of the Company’s CHEMSAS® technology is to speed up the discovery and development of novel drug therapies, permitting Cotinga to build a pipeline of potential drug candidates quicker and with a higher probability of success than traditional methods.

CHEMSAS® is a multi-staged computational platform technology. It is based upon a hybrid of machine learning technologies and proprietary algorithms, which allows prediction of biological activity from molecular structures.

Cotinga Pharmaceuticals’ lead compound is COTI‐2. It has a novel p53‐dependent mechanism of action with selective and potent anti-cancer activity.  COTI‐2 is initially undergoing evaluation for the treatment of gynecologic cancers and head and neck squamous cell carcinoma in a Phase 1 clinical trial at the MD Anderson Cancer Center at the University of Texas and the Lurie Cancer Center at Northwestern University. Cotinga has secured orphan drug status in the U.S. for COTI‐2 for the treatment of ovarian cancer.

Cotinga’s second lead compound is COTI-219. This is a novel oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS function.  KRAS mutations occur in up to 30 percent of all cancers. COTI-219 is undergoing IND-enabling studies to support a regulatory submission. COTI-2 and COTI-219 are the first compounds derived with the benefit of CHEMSAS® to be developed by Cotinga Pharmaceuticals.

The Company’s technology also includes ROSALIND™. This is a simulation platform designed to provide better personalized treatment options based on the genetic profile of the patient’s cancer.

In March, Cotinga Pharmaceuticals announced that it submitted an updated clinical package to regulatory authorities to expand its continuing Phase 1 trial of COTI-2. The protocol amendment will expand the clinical trial to evaluate COTI-2 as a combination therapy in a broad array of cancers.

The ongoing Phase 1 trial of COTI-2 is presently evaluating COTI-2 as a monotherapy for the potential treatment of gynecological malignancies and HNSCC. In 2017, Cotinga Pharmaceuticals announced top-line data from the gynecological malignancies arm of the trial demonstrating COTI-2 was generally safe and well-tolerated. In addition, COTI-2 exhibited an encouraging pharmacokinetic/pharmacodynamic profile and signals of efficacy.

Today, Cotinga Pharmaceuticals announced that it and its collaborators from MD Anderson Cancer Center and Northwestern Medicine will present data on COTI-2, Cotinga’s lead compound, at the American Association for Cancer Research (AACR) Annual Meeting 2018 taking place April 14-18, 2018 in Chicago, Illinois.

Cotinga Pharmaceuticals, Inc. (COTQF), closed Tuesday's trading session at $0.3078, even for the day. The average volume for the last 60 days is 1,002 and the stock's 52-week low/high is $0.10/$3.277.

chart

Intelligent Cloud Resources, Inc. (ITLL)

4-Traders, Business Wire, and Market Exclusive reported previously on Intelligent Cloud Resources, Inc. (ITLL), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Intelligent Cloud Resources, Inc. has been working to provide cloud enabler and cloud broker services to small and medium sized organizations in Canada. In addition, the Company’s plan is to expand to such organizations in the United States. OTCQB-listed, the Company has its corporate headquarters in Oakville, Ontario.

Intelligent Cloud Resources’ Fonia “All Access Mobile” is an end-to-end Mobile solution. The Company said that the launch of the Fonia “All Access Mobile” platform will be a strong consumer oriented addition to its product family.

Fonia "All Access Mobile" works to serve individuals, regardless of their credit score, through an MVNO (Mobile Virtual Network Operator) Fonia Mobile (and Fonia Financial). The service will bundle a traditional handset sale with a hybrid phone rate plan (a mix of prepaid and post-paid plans) and a prepaid MasterCard.

Fonia offers phones and plans with its Fonia “All Access Mobile”. In addition, all subscribers receive a premium MasterCard. A user of Fonia can obtain another 30-day no-contract plan, as well as save time with Auto-Refill.

Intelligent Cloud Resources shares networks with the four leading carriers. A customer can activate with a new number. A customer can also activate and transfer their number.

Intelligent Cloud Resources has an agreement to obtain a perpetual license to provide Leagoo Smart Phones and the innovative Fonia "All Access Mobile" platform to the territory of Florida.

The Company announced in July of 2017 the successful completion of the previously announced acquisition of the innovative Fonia “All Access Mobile” platform perpetual license and premier Leagoo Smart Phones for the territory of Florida. This will be the first step in a program to launch the product and service in numerous territories.

Fonia’s service offerings are backed by Mastercard, AT&T, Transunion, Leagoo, and 7-Eleven. Intelligent Cloud Resources’ emphasis is the exploitation of proprietary mobile banking and telecommunication solutions custom tailored for the 118 million unbanked and underbanked adults living in the United States.

Fonia is transparent with no hidden fees or charges. Regarding mobile, the Company has partnered with AT&T to bring its customers the Fonia private mobile network. A customer gets a roaming SIM card that covers all of North America, without long distance charges.

Intelligent Cloud Resources, Inc. (ITLL), closed Tuesday's trading session at $0.115, even for the day. The average volume for the last 60 days is 17,841 and the stock's 52-week low/high is $0.10/$0.99.

chart

BioElectronics Corporation (BIEL)

StreetInsider, Barchart, and InvestorsHub reported on BioElectronics Corporation (BIEL), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices. The Company’s unique medical devices safely and effectively treat chronic and acute pain by way of an innovative mechanism of non-invasive sub-sensory neuromodulation. BioElectronics is based in Frederick, Maryland.

The Company’s products include ActiPatch and RecoveryRx®. ActiPatch® provides advanced long-lasting chronic pain relief using Electromagnetic Pulse Therapy. It is a new and clinically proven drug free technology in the battle against chronic pain.

RecoveryRx® utilizes pulsed electromagnetic therapy to lessen pain and inflammation resulting in accelerated patient recovery and improved comfort. For medical professionals, the RecoveryRx® medical device provides a safe and cost-effective pain management therapy.

BioElectronics products also include Smart Insole™, Allay® Menstrual Pain Relief, and HealFast® Veterinary Pain Relief. The Smart Insole™ comprises Electro-Pulse micro medical devices. These are embedded in comfortable heel gel inserts.

Allay® is an award winning drug-free micro medical device. It utilizes Electromagnetic Pulse Therapy to lessen menstrual pain and discomfort. HealFast® Therapy is a drug-free therapy for horses, cats and dogs. It reduces swelling and pain while it speeds healing of muscle and tendon injuries, sores, as well as incisions.

Recently, BioElectronics announced that the UK’s (United Kingdom’s) government funded public health service, National Health System (NHS), approved the Company’s application to cover and pay for ActiPatch® Musculoskeletal Pain Therapy. The ActiPatch is a drug-free, wearable medical device. It regulates peripheral nerve activity to provide pain relief.

The NHS based its decision considering strong clinical evidence and a health economics study that found that ActiPatch considerably lessened pain and improved quality of life. This is while decreasing overall healthcare costs by 42 percent (58.5 percent reduction in physician appointment costs, 35 percent reduction in prescription medication costs).

Last month, BioElectronics announced the start of a clinical study investigating the efficacy of its RecoveryRx® device for postoperative pain management and recovery following total knee arthroplasty surgery. The clinical study will involve 40 subjects who are already scheduled for a knee replacement. Each subject will be randomly assigned to receive an active device or placebo device. Enrollment into the study has started. The expectation is that the study will be completed in December 2018.

In case studies, RecoveryRx® has shown to be of significant clinical value regarding postoperative pain management and improving long term pain management in subjects undergoing total knee replacement.

BioElectronics Corporation (BIEL), closed Tuesday's trading session at $0.0012, even for the day, on 37,694,210 volume with 83 trades. The average volume for the last 60 days is 52,773,105 and the stock's 52-week low/high is $0.0005/$0.0014.

chart

BAB, Inc. (BABB)

Greenbackers, Marketbeat, SmallCapVoice, Zacks, and OTC Markets Group reported previously on BAB, Inc. (BABB), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

BAB, Inc. franchises and licenses Big Apple Bagels®, My Favorite Muffin®, SweetDuet® frozen yogurt, and Brewsters’® Coffee. In addition, the Company engages in the sale of bagels, muffins, and coffee through nontraditional channels of distribution, including under licensing agreements. BAB Systems, Inc. is the Company’s franchising subsidiary. OTCQB-listed, BAB has its corporate office in Deerfield, Illinois.

BAB’s My Favorite Muffin is a national chain of fast-casual restaurants with hand-crafted products. BAB’s SweetDuet® is a Duet Yourself® frozen yogurt bar. It includes a complete offering of gourmet muffins. BAB’s Big Apple Bagels is a national chain of fast-casual restaurants.

The Company garners its revenues primarily from the ongoing royalties paid to it by its franchisees and also receipt of initial franchise fees. Furthermore, BAB receives revenue from the sale of licensed products (My Favorite Muffin mix, Big Apple Bagels cream cheese, Big Apple Bagels frozen bagels, and Brewster's coffee).

Royalty fees represent a 5 percent fee on net retail and wholesale sales of franchised units. BAB earns a licensing fee from the sale of BAB branded products from a third-party commercial bakery, to the franchised and licensed units. The Company’s nontraditional channels of distribution are Kohr Bros. and Green Beans Coffee.

Moreover, included in licensing fees and other income is Operation's Sign Shop revenue. The Sign Shop provides the bulk of signage. This includes but is not limited to, posters, menu panels, outside window stickers, and counter signs to franchisees to provide consistency and convenience.

The Company’s Brewsters' Coffee® hand picks only the top 2-3 percent of Arabica beans from around the world. Brewsters’ hand roasts its beans in small batches. Also, BAB’s has Jacobs Bros. Bagels (frozen raw dough and par-baked varieties).

Last week, BAB announced its financial results for Q1 ended February 28, 2018. For the quarter, the Company had Revenues of $500,000 and Net Income of $101,000, or earnings of $0.01 per share. This is in comparison to Revenues of $493,000 and Net Income of $53,000, or earnings of $0.01 per share for the quarter ended February 28, 2017.

BAB, Inc. (BABB), closed Tuesday's trading session at $0.6502, down 7.10%, on 100 volume with 1 trade. The average volume for the last 60 days is 6,001 and the stock's 52-week low/high is $0.61/$0.82.

chart

Broadway Gold Mining Ltd. (BDWYF)

Stockhouse, Streetwise Reports, Barchart, and InvestorsHub reported on Broadway Gold Mining Ltd. (BDWYF), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Broadway Gold Mining Ltd. concentrates on development-stage projects with advanced exploration potential. A resource company, it owns a 100 percent interest in the Madison copper-gold project in the Butte-Anaconda mining area of Montana. Broadway Gold Mining is headquartered in Vancouver, British Columbia. The Company lists on the OTC Markets’ OTCQB.

The Madison copper-gold project is permitted for exploration. It contains a past-producing underground mine that Broadway Gold Mining has refurbished. The Company is expanding known copper and gold zones that remain open for development in the mine's perimeter.

Broadway’s exploration program has identified new anomalies across its extensive land package. These provide drill targets believed to be associated with large-scale porphyry mineralization.

Last year, Broadway Gold Mining identified copper-gold porphyry targets at Madison, supported by a newly assembled geological model. Phase I and II drilling in 2017 returned high-grade gold and copper intersections from shallower skarn zones. Numerous high-priority targets, including porphyry, will be the focus of Phase III drilling.

In October 2017, Broadway Gold Mining announced the discovery of a new latite porphyry zone of mineralization at its Madison project. The Company announced in November of 2017 that, as a result of its earlier porphyry discovery, it staked additional ground to cover favorable geological and geophysical targets in the area of its 100 percent-owned Madison copper-gold project.

These new claims are contiguous to the south of Broadway’s active exploration area. The new claims extend the current Madison property footprint to 2,514 acres. The Company’s Phase III drilling program continues.

Broadway is fully funded for completion of the program. Deeper geophysical targets from the 2017 survey appear to trend through the original property boundary onto the newly acquired claims.

Last month, Broadway Gold Mining provided an update on its Phase III surface drilling program at its 100 percent-owned Madison copper-gold project in the historic Butte-Anaconda mining region of Montana. The Company recently documented a well-mineralized, two-mile-long geological, geophysical and geochemical trend at Madison. Important highlights so far include confirming a new porphyry discovery in a regional trend near the Butte region.

Latite porphyry was intercepted in holes C17-24 and C17-27. Moreover, the Company states that the porphyry body appears to be of substantial size with intercepts to date measuring up to 234 meters and open in all directions.
Furthermore, anomalous gold, silver, manganese, lead, sulfur, strontium and zinc were identified in the phyllically altered latite. In addition, geochemical analysis indicates characteristics consistent with gold or gold-copper-rich systems.

Broadway Gold Mining Ltd. (BDWYF), closed Tuesday's trading session at $0.155, even for the day. The average volume for the last 60 days is 27,054 and the stock's 52-week low/high is $0.1429/$0.984.

chart

MannKind Corporation (MNKD)

MarketWatch, InvestorsHub, and Stockhouse reported on MannKind Corporation (MNKD), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products. These products are for patients with diseases such as pulmonary arterial hypertension and diabetes. In addition, MannKind employs field sales and medical representatives across the U.S. A biopharmaceutical enterprise, the Company has its corporate office in Westlake Village, California. MannKind also has a state-of-the art manufacturing facility in Danbury, Connecticut.

MannKind is now commercializing Afrezza® (insulin human) inhalation powder. This is the Company’s first Food and Drug Administration (FDA)-approved product. Afrezza® is the only inhaled rapid-acting mealtime insulin in the U.S. It is available in the U.S. by prescription from pharmacies throughout the nation.

Afrezza® is available through prescription only. It is a rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. MannKind’s single-use and reusable Inhalers are breath-powered. As a result, they require only the patient’s inhalation effort to deliver the powder.

One breath delivers one dose. MannKind’s inhalers efficiently focus the energy supplied by the patient’s breath directly onto the dry powder. This results in high delivery performance.

Afrezza® is taken at the start of a meal using the specially designed inhaler. Afrezza® dissolves fast upon inhalation to the deep lung. It delivers insulin quickly to the bloodstream. Peak insulin levels are achieved within 12 to 15 minutes of use and help to control post-meal blood sugar spikes that affect HbA1C levels.

Afrezza® uses MannKind’s proprietary Technosphere® formulation technology. The foundation of this technology is on a class of organic molecules designed to self-assemble into small particles onto which drug molecules can be loaded.

The Company’s dry powder formulations are based on FDA-approved excipients. This includes fumaryl diketopiperazine (the excipient used in Technosphere® inhalation powders) and mannitol. MannKind’s formulations result in powders that have particles within the consistent and narrow particle size range necessary for delivery to the deep lung, and without the need for sizing, milling, or blending.

MannKind’s pipeline includes Epinephrine Technosphere® for anaphylaxis; and Treprostinil Technosphere® for Pulmonary Arterial Hypertension (PAH). Its pipeline also includes Palonosetron Technosphere® for Chemotherapy-Induced Nausea and Vomiting (CINV).

In March, MannKind announced that it would start enrolment of patients in a Phase 1 clinical study of Treprostinil Technosphere (TreT) under an Investigational New Drug (IND) application filed with the FDA. TreT is proposed as a drug-device combination product for the treatment of patients with pulmonary arterial hypertension (PAH), using a small, portable, breath-powered inhaler intended to simplify drug dosing. The main goal of the Phase 1 clinical study is to investigate the safety, tolerability, and pharmacokinetics of TreT in healthy volunteers after dosing by oral inhalation.

MannKind will be featured as a presenting company at the H.C. Wainwright Annual Global Life Sciences Conference at 1:45 PM (CET) on April 9, 2018.  The conference is taking place at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.

MannKind Corporation (MNKD), closed Tuesday's trading session at $2.19, up 0.92%, on 1,215,304 volume with 4,119 trades. The average volume for the last 60 days is 3,640,108 and the stock's 52-week low/high is $0.6662/$6.96.

chart

Data Storage Corp. (DTST)

Buzz Stocks, Penny Pick Finders, Penny Picks, PennyStockProphet, Planet Penny Stocks, SecretStockPromo, Stock Onion, EpicVIP Group, TopPennyStockMovers, Real Pennies, Bull Trends, Information Solutions Group, StockMister, Penny Dreamers, Epic Stock Picks, Wolf of Penny Stocks, ActualGains, PennyStockRumors.net, PennyStocks24, PricelessPennyStocks, Stock Twiter, AlphaPennyStock, Investor News Source, RockingPennyStocks, and Stock Guru reported previously on Data Storage Corp. (DTST), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Data Storage Corp. provides cloud-based technology solutions. A Cloud Services Provider, the Company provides hardware, software-as-a-service (SaaS), managed IT (Information Technology) services, installation, and maintenance, focused on compliance, message archiving, analytics, disaster recovery, and business continuity. Data Storage provides its solutions and services through leveraging leading technologies. These include virtualization, cloud computing, as well as cloud storage. Message Logic is a business unit of the Company. Data Storage is based in Garden City, New York.

The Company provides business-to-business (B2B) cloud storage and cloud computing solutions and services in the U.S. and Canada. Data Storage helps organizations internationally in managing and protecting their data, minimizing downtime, and lessening costs while ensuring compliance with regulations. It provides its solutions and services to healthcare, banking and finance, distribution services, manufacturing, construction, education, and government industries.

Data Storage’s solutions include offsite data protection and recovery services, High Availability (HA) replication services, email compliance solutions for e-discovery, continuous data protection, data de-duplication, virtualized system recovery, and telecommunications recovery services. The Company’s Message Logic business unit delivers regulatory compliant email archiving and analytics to enterprises globally.

Message Logic’s MLArchiver provides a solution uniting archiving, records management, eDiscovery, and analytics to deliver a new level of advanced capabilities. Additionally, Data Storage’s Secure Infrastructure & Services centers on providing infrastructure as a service (IAAS). It specializes in power systems, iseries, and AS400 users.

Data Storage has acquired ABC Services and ABC Services II, a 25-year provider of IBM equipment, IAAS, managed and professional services, including the remaining 50 percent ownership of Secure Infrastructure and Services. With this acquisition, Data Storage expands its current solutions. This includes email archival and compliance, Recovery Cloud, Office 365, IBM DR and Cloud Servers. This is while taking advantage of ABC’s network and data security, managed services and equipment.

Recently, Data Storage announced its formation of Nexxis, Inc. This is a new subsidiary of the Company that will concentrate on the development of next-generation voice and data services intended to help companies expedite their communications, increase revenue and lessen costs.

Mr. John Camello will serve as President of Nexxis. Mr. Camello is a veteran telecommunications entrepreneur and executive. He has considerable experience in providing nationwide telecommunication services. Mr. Camello said, “I’m excited to lead this new venture.  We intend to offer standalone voice, internet and transport services, as well as complete next-generation voice and data solutions that will incorporate auto failover with the goal of delivering unmatched reliability and value.

Data Storage Corp. (DTST), closed Tuesday's trading session at $0.10, up 22.03%, on 4,275 volume with 4 trades. The average volume for the last 60 days is 230,713 and the stock's 52-week low/high is $0.068/$1.00.

chart

The QualityStocks Company Corner

PotNetwork Holding Inc. (POTN)

The QualityStocks Daily Newsletter would like to spotlight PotNetwork Holding Inc. (POTN).

PotNetwork Holdings Inc. (OTC Pink:POTN) On Tuesday, April 3rd, 2018, (“Company”) announced the release of audited consolidated financial statements reporting 2017 sales of $14.5 million, with gross profits of $5,180,865, and, despite making large reinvestments in its future growth, the Company showed positive net income of $178,918. To view report in its entirety, visit otcmarkets.com.

PotNetwork Holding, Inc. (POTN), based in Fort Lauderdale, Florida, is a holding company. The company’s First Capital Venture Co. subsidiary is the owner of Diamond CBD, Inc., a producer of widely-distributed CBD hemp extracts and the primary operating entity of PotNetwork Holding.

Diamond CBD is made up of chemists and other scientists focused on developing and producing very high-quality CBD oil over a broad range of products, based upon a thorough understanding of the various natural molecules found in hemp and their particular properties. All products are made with federally legal cannabidiol (CBD), and are available in hundreds of flavors and sizes. The company emphasizes a dedication to 100% natural lab-tested CBD ingredients, with a carefully monitored process all the way from the source farm, through production, and final delivery to retail shelves.

PotNetwork, through Diamond CBD, delivers products to all 50 states, as well as internationally, and controls 15 CBD brands. The company lists the following product brands:

  • Diamond CBD Gummies – Diamond CBD branded edible gummies made from crystal isolate. Available in a variety of flavors and gummy styles, including rainbow bites, mini fruit, gummy worms, sour snakes, and more.
  • Chill Gummies – Chill gummies are more robust than its counterpart, the “Relax” gummy line. Chill Gummies are edible CBD gummies available in a wide variety of flavors, strengths, and styles including gummy bears, sour snakes, rainbow bites, watermelon slices, sour snakes, rainbow bites, peanut butter chocolate, ocean gummies, gummy worms, gummy rings and more.
  • CBD Liquid Gold – CBD Liquid Gold is derived from naturally grown industrial hemp plants, certified by USA labs and then carefully mixed with a patent-pending (non-PG) all-natural base formulation.
  • Blue CBD – Blue CBD Crystal Isolate is a high-end vapor liquid and oral drop infused with premium CBD rich hemp oil. CBD liquids are Premium Gold quality and test at a 7X higher concentration.
  • Relax Gummies – Relax Gummies give a lighter effect of CBD with some natural flavors in comparison to its counterpart Chill Gummies. Relax Gummies are perfect for anyone with a sweet tooth that’s looking for a lighter effect without sacrificing quality or taste.
  • Premium Hemp Liquid Pet – CBD For Pets is a new and refreshing product from Diamond CBD for all the millions of pets out there. It is an organic product and also has unique flavors in it.
  • CBD Re-Leaf – Disposable, long-lasting, and ready to Use CBD Re-leaf vaping pens available in a variety of flavors. Easily take CBD anywhere on the go.
  • Relax Extreme CBD – Relax Extreme CBD Oil provides a high-quality, high-strength dose of CBD through oral drops. It is very easy to use and works instantly. Simply place a drop under the tongue. Available in various strengths.
  • CBD Double Shot – CBD Double Shots are specifically designed for one-time use. Easily squeeze the package in your mouth and swallow; it’s that simple. Take it anywhere you go. Relaxation is now conveniently in your pocket. Drinkable CBD shots provide a quick boost of relaxation on the go. Available in various flavors.
  • Chill Pill – CBD infused capsules available in various strengths. Relax, take a Chill Pill.

Over 1.2 million people currently use cannabis, including CBD products, for medical application, including cancer, epilepsy, and depression. By sourcing hemp outside the U.S., the company avoids current federally-based legal problems involved in growing cannabis domestically. In the meantime, PotNetwork Holding continues to target a large and rapidly developing cannabis market, expanding from $6.5 billion in 2016, to an expected $30 billion in 2021 (Forbes), and $50 billion in 2026 (Bloomberg). The cannabidiol market alone is projected to reach $2.1 billion in 2020, a 700% increase from 2015. PotNetwork Holding Inc. plans to expand its subsidiaries as well as make strategic acquisitions.

PotNetwork Holding Inc. (POTN), closed Tuesday's trading session at $0.395, up 35.74%, on 11,387,649 volume with 2,168 trades. The average volume for the last 60 days is 12,006,381 and the stock's 52-week low/high is $0.0006/$0.957.

Recent News

chart

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX).

ChineseInvestors.com, Inc. (OTCQB: CIIX) is reaching the global Chinese-speaking community with regard to bitcoin — with TV broadcasts, an online site, an ATM in the lobby of its San Gabriel, California, headquarters and plans to mine cryptocurrency from a datacenter near Seattle. The company is exploring cryptocurrency mining following its recent purchase of mining machines (http://cnw.fm/VL4nB).

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.

ChineseInvestors.com (CIIX), closed Tuesday's trading session at $0.5145, up 9.47%, on 17,942 volume with 26 trades. The average volume for the last 60 days is 74,147 and the stock's 52-week low/high is $0.40/$1.58.

Recent News

chart

EVIO, Inc. (EVIO)

The QualityStocks Daily Newsletter would like to spotlight EVIO, Inc. (EVIO).

The need for cannabis testing companies, spurred on by increasing number of states legalizing medical and recreational cannabis, was further underscored in the wake of the aforementioned tragedy and others like it, tragedies that cannabis testing companies like Oregon-based industry leader EVIO, Inc., (OTCQB: EVIO) are dedicated to preventing.

EVIO, Inc. (EVIO), via the EVIO Labs division, is the nation’s leading provider of accredited analytical testing, scientific research and advisory services to the regulated cannabis industry. EVIO Labs provides state-mandated ancillary services that are required to ensure the safety and quality of the nation’s cannabis supply. EVIO Labs has performed over 50,000 tests during the past two years and grown from one laboratory in Oregon to nine labs spanning California, Oregon, Colorado, Massachusetts and Florida.

EVIO Labs is driving the cannabis testing industry by providing clients nationwide with consistent high-quality cannabis analytical services backed by quality control assurances. The company also provides advisory services that help cannabis producers and retailers enhance production processes, achieve regulatory compliance and meet quality goals.

EVIO Labs is on track to open 18 laboratories by the end of 2018 at locations around the United States. The Oregon-based company provides analytical services that include testing cannabis and industrial hemp flower, extracts and infused products. The labs specialize in performing the following tests:

  • Cannabinoid analysis, which properly characterizes the many primary cannabinoids found in cannabis including THC, CBD, and several other cannabinoids.
  • Terpene analysis, which identifies the aromatic compounds of the plant (terpene), which can help identify the therapeutic potential of a cannabis flower or extract.
  • Moisture content and water activity, which measure the moisture levels of dried cannabis and are indicators of microbiological growth potential.
  • Pesticide residue analysis of over 100 different pesticides, herbicides, fungicides, growth regulators and other agrochemicals that may be present on cannabis.
  • Detection of harmful residual solvents left behind in the cannabis extract production process.
  • Microbial testing screen for bacterial and fungal contamination in cannabis and cannabis-infused products.
  • Detection of heavy metals including lead, cadmium, mercury, and arsenic.

EVIO Labs is rapidly becoming the nation’s leading cannabis biotechnology company. Led by a management team with extensive experience in designing and rolling out successful business ventures, product research and development, regulatory and compliance protocols, medical cannabis cultivation, production and analytical chemistry techniques, EVIO Labs is prepared to take advantage of today’s fastest growing industry.

EVIO, Inc. (EVIO), closed Tuesday's trading session at $1.25, up 2.46%, on 51,048 volume with 49 trades. The average volume for the last 60 days is 86,892 and the stock's 52-week low/high is $0.47/$2.70.

Recent News

chart

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences, Inc. (OTCQB: PBIO) today announced financial results for the fourth quarter and fiscal year ended December 31, 2017, provided a business update, and offered limited guidance for FY2018.

Pressure BioSciences Inc. (OTCQB: PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Tuesday's trading session at $3.75, up 2.74%, on 3,201 volume with 3 trades. The average volume for the last 60 days is 1,730 and the stock's 52-week low/high is $0.70/$10.50.

Recent News

chart

SinglePoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

SinglePoint Inc. (OTCQB:SING) announces the official launch of the freshly revamped SingleSeed.com website, focused on selling cannabidiol (CBD) based products direct to consumer. A subsidiary of SinglePoint, SingleSeed has been actively operating in the cannabis space since 2014.

SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed Tuesday's trading session at $0.034, up 6.25%, on 13,622,198 volume with 591 trades. The average volume for the last 60 days is 7,594,971 and the stock's 52-week low/high is $0.0132/$0.415.

Recent News

chart

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE).

Global Payout Inc. (OTCPink:GOHE) ("Global") is pleased to announce that its subsidiary MoneyTrac Technology, Inc. ("MTRAC", the "Company") announced today that its partner, Integrated Compliance Solutions (ICS) has committed to serving as the compliance arm of MTRAC, a full-service payment solution powered by GreenBox's state-of-the-art closed loop blockchain technology.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout’s fully configurable “banking-in-a-box” web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today’s banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout’s management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and “high-risk” market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and “high-risk” enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions.

Global Payout, Inc. (GOHE), closed Tuesday's trading session at $0.01463, up 5.25%, on 11,099,794 volume with 244 trades. The average volume for the last 60 days is 10,992,233 and the stock's 52-week low/high is $0.0123/$0.16.

Recent News

chart

FANDOM SPORTS Media Corp. (CSE: FDM) (OTC: FDMSF) (FRANKFURT: TQ42)

The QualityStocks Daily Newsletter would like to spotlight FANDOM SPORTS Media Corp. (FDMSF).

Fan-focused entertainment company FANDOM SPORTS Media Corp. (CSE: FDM) (OTC: FDMSF) (FRANKFURT: TQ42) this morning announced that it has been selected by IBM to take part in the tech giant’s exclusive ‘Blockchain Digital Mentorship Program’.

FANDOM SPORTS Media Corp. (CSE: FDM) (OTC: FDMSF) (FRA: TQ42) taps into the primal, unfiltered passion of sports fans from around the world by providing an uncensored social media platform delivered through the FANDOM SPORTS mobile app. As an aggregator, curator and instigator of both company-created and user-generated content, the FANDOM SPORTS app is designed to entertain sports enthusiasts with real-time, interactive content on a mobile only app that offers bragging rights and real-life rewards. True sports addicts will appreciate an app that allows fans to pick a fight or create their own FanFights and rule over others as they trash talk their way to victory. The FANDOM SPORTS proprietary data centric “argument engine” measures and scores opinionated dialogue, as well as establishes consensus, giving fans and users the ability to dive deeper into one-of-a-kind cultural moments, cheer on favorite sports teams and slam dunk some sweet rewards.

Building on the company’s tag line – “Pick a Fight” – the FANDOM SPORTS app provides an always fresh, authentic rush of deeper-than-surface interactive content that resonates with the targeted age demographic of 18-34. Intense sports fans aren’t afraid of stepping up to the plate to engage other users by unleashing their opinions within the app’s structured debate resolution tool coined “FanFights.” Sports-loving fans can explore, gloat, vote, invite friends, create provocative FanFight topics and play to win while inside the FANDOM SPORTS app, which is currently available in the Apple App store and coming to the Google Play store imminently. The company’s self-learning algorithm predicts and collects user preferences while building relevant personalized FanFight channels, bringing the concept of competitive, in-your-face conversation to a whole new level of sports entertainment.

The FANDOM SPORTS app is free to play (F2P) with in-app purchase and subscription capabilities. The gaming aspect of the ecosystem is built on behavioral economics and delivers multiple revenue streams by maximizing average revenue per daily active user (ARPDAU) and user-generated content (UGC), with select placement of high-impact video and moment-based marketing as part of the brand-sponsored FanFights and in-app offers. The global platform enables applications (either FANDOM SPORTS created or 3rd party apps) to be operated in partnership with leading sports themed brands, leagues, and service providing companies within three verticals – live action, eSports, & fantasy – from around the world by supplying “interactive sports entertainment” to fans. The FANDOM SPORTS platform creates a bullet-proof snapshot of the app’s fan base through a Blockchain supported “PlayerCard” in tandem with the “Engagement Score”, which doubles as an invaluable acquisition and retention tool for its business operators. FANDOM SPORTS hosted transactions are placed on the distributed ledger, making them immutable and public to verified users interacting within the business ecosystem. Tracking this digital footprint provides extremely valuable metadata generated by users’ very dynamic behavior and sports passion.

FANDOM SPORTS’ Brand and Sponsorship partners are harnessing the affluent sports fans age 18-34 with integrated marketing content and service experience. The moments-based marketing integration will translate through FanCoin redemption, in exchange for items provided by programs established by FANDOM SPORTS and its clients. These programs are a key part of the business model and covers, as an example, the following partners; Sports Leagues, TelCo’s service offerings, and Content owners (i.e. FANDOM SPORTS provides new paying customers to the owners of pay-per-view platforms).

“Pick A Fight. Talk Trash. Get Rewarded.”

FANDOM SPORTS Media is an entertainment company that aggregates, curates and produces unique fan-focused content.

The FANDOM SPORTS App is the Company’s core product, which is the ultimate destination for unfiltered raw sports talk. The app allows passionate sports fans to unleash their primal sports passions, pick fights and earn rewards.

So download the app and bring your crew. Talking trash is better with friends. The more you invite, the more FanCoins you earn.

You may also visit the Company’s website at www.fandomsportsmedia.com or contact them directly at info@fandomsportsmedia.com.

DISCLAIMER:

The CSE has not reviewed and does not accept responsibility for the adequacy and accuracy of this information. This news release may contain forward-looking statements. These forward-looking statements do not guarantee future events or performance and should not be relied upon. Actual outcomes may differ materially due to any number of factors and uncertainties, many of which are beyond the Company’s control. Some of these risks and uncertainties may be described in the Company’s corporate filings (posted at www.sedar.com).

The Company has no intention or obligation to update or revise any forward-looking statements due to new information or events

FANDOM SPORTS Media Corp. (FDMSF), closed Tuesday's trading session at $0.107, even for the day. The average volume for the last 60 days is 24,148 and the stock's 52-week low/high is $0.025/$0.3911.

Recent News

chart

Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF)

The QualityStocks Daily Newsletter would like to spotlight Choom Holdings Inc. (CHOOF).

NetworkNewsAudio announces the Audio Press Release (APR) titled "Countdown to Canada's Recreational Cannabis Industry Enters Retail Territory," featuring Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF). To hear the NetworkNewsAudio version, visit http://nnw.fm/PZ2Xm. To read the original editorial, visit http://nnw.fm/By9mN.

Choom Holdings Inc. (OTCQB: CHOOF) (CSE: CHOO) channels the laid-back spirit of Hawaii to the Okanagan region of British Columbia with a generous nod to the inspirational, yet unofficial, history of the 1970s “Choom Gang,” a group of buddies in Honolulu (including former President Barack Obama) who knew how to relax with “choom,” the local’s term for marijuana. Choom’s trademark slogans pivot off another unconventional phrase (“Say Hello to…”), bringing a heady dose of good times and good friends together as the company invites investors to “Say Hello to Choom™” as it lights up the adult recreational cannabis market in Canada.

Choom™ has been an ACMPR (Access to Cannabis for Medical Purposes Regulations) applicant since November 2013 in Vernon, B.C. The company’s first application has received security clearance and is now in the detailed review stage. They also recently announced their second late-stage ACMPR application, which is in its confirmation of readiness stage. Cannabis Compliance Inc. has been retained to help expedite Choom’s initial license applications to ensure the company’s readiness for legalization of recreational marijuana in Canada mid-summer 2018.

True to the company’s character, Choom™ is retrofitting two large facilities – No. 1 in Vernon, B.C., and No. 2 on Vancouver Island – to house its cannabis growing facilities. Phase 1 of the Vernon property will provide Choom™ with 6,800 square feet of growing space, capable of producing 660 kg/year of cannabis at an estimated revenue of $6.6 million, excluding oils. The company expects this facility to be completed by July 2018, the same month that Canada is expected to formally legalize recreational marijuana for adult use. A potential Phase 2, to be completed by the end of 2018, would add another 6,800 square feet for a total of 1,500 kg/year capacity, which would nearly double No. 1’s revenue. A Level 9 vault is also planned with a storage capacity of 15,000 kg. While the No. 2 facility on Vancouver Island is smaller – 4,500 square feet – its retrofit is also slated to be completed by July 2018. Plans include doubling this space as well, which would add about $9 million in annual revenue, excluding cannabis oils.

Choom™ announced its retail dispensary strategy with the intention of establishing market leadership in reaching the Canadian cannabis consumer. The partner program is already in the retail space design stage as the company seeks to build a chain of branded retail cannabis dispensaries in jurisdictions in Canada where recreational cannabis is legal. Choom™ Stores will have a cool, modern layout and design created to emit an authentic “Aloha” vibe. Choom™ is all about producing high-grade cultivars and curating them for a bigger audience.

A savvy, experienced management team includes Chris Bogart, president and CEO; John Oh, R.P.I.C., Operations Manager; Robert Bayrack, Master Grower, S.P.I.C.; and Adrian Robinson, Strategic Advisor. Bogart has over two decades of international experience in capital markets and was a co-founder of InMed Pharmaceuticals and Magnum Uranium. He has structured complex equity financing transactions in the U.S., Europe and Canada. Bogart is joined on the Board of Directors by Kevin Pull, Stephen Tong and John Oh.

While the medical marijuana industry is expected to double by 2021 to 500,000 registered users, the true highlight of the recreational cannabis represents the key cultural shift set to launch in Canada. With an estimated $4.9B to $8.7B retail market coming, now is the right time for a Recreation Brand like Choom™ to be involved in this growing industry. Establishing and maintaining Choom™ premium brand loyalty is a key factor in the company’s growth strategy. Get ready to “Say Hello” to opportunity, good times and good friends with Choom™.

Choom Holdings Inc. (CHOOF), closed Tuesday's trading session at $0.705, off by 4.60%, on 117,132 volume with 126 trades. The average volume for the last 60 days is 101,663 and the stock's 52-week low/high is $0.125/$0.8612.

Recent News

chart

Victory Square Technologies Inc. (CSE: VST) (OTC: VSQTF) (FRANKFURT: 6F6) (WKN: A2AKL8)

The QualityStocks Daily Newsletter would like to spotlight Victory Square Technologies Inc. (VSQTF).

The biggest boost to VR technology potentially comes from the integration of blockchain technology. This is where blockchain companies could bring the true potential of VR into life. A short list of companies at the forefront of this technology includes Victory Square Technologies, Inc. (OTC: VSQTF) (CSE: VST).

Victory Square Technologies Inc. (VSQTF) is a venture builder that creates, funds and empowers entrepreneurs working in the fields of blockchain technology, virtual reality, artificial intelligence, personalized health, gaming and film. As a technology incubator, Victory Square invests in game-changing entrepreneurs who are provided access to education programs, global mentorship networks, distribution partners, creative workspaces, resources, and other forms of operational support to help them scale internationally.

Victory Square has made multiple early partnerships and investments in the blockchain space. Approximately three years ago the company incubated and invested in BTL Group, which is now a $150 million dollar TSX-listed company offering blockchain solutions across multiple industries with particular focus on the finance, energy and gaming sectors. BTL’s showcase product – Interbit – is a blockchain platform that facilitates the rapid development of business applications that dramatically improve efficiency. Some of the world’s largest institutions are using Interbit to explore new opportunities on private blockchains.

A new social sports betting platform to be developed by Victory Square’s wholly owned subsidiary, FansUnite Media Inc. As a social sports data platform, FansUnite relies on robust data to allow members of its community to engage with like-minded individuals by collaborating, discussing, and predicting the winners of sporting events with a free virtual currency. The integration of blockchain technology into FansUnite’s social sports data platform could also lead to blockchain initiatives developed by other divisions and subsidiaries of Victory Square.

Integral to the FansUnite platform is the introduction of FAN Tokens, an in-game currency purchased with the cryptocurrency Ethereum that token holders can use to place wagers. FansUnite members will be able to earn FAN Tokens through participation in any number of networking effects identified in the company’s Bounty program.

“Blockchain technology and the inherent security it provides will enable us to push every envelope we can to build the most dynamic and responsive social sports betting platform,” said Darius Eghdami, Co-Founder and Chief Executive Officer of FansUnite. “The opportunity to secure data through Blockchain certainly appeals to the accountant in me and we are confident it will become the gold standard among sports betting sites around the world.”

Company subsidiary Victory Square Health Inc., which serves as the venture arm dedicated to companies focused on the development of solutions in personalized health technologies, has also invested in Personalized Biomarkers Inc. (PBI). PBI develops test kits that reliably predict the expected response to a number of therapies prior to prescription, with an initial focus on diabetes. Within this field, five potential biomarkers have been identified, allowing PBI to enter a $4 billion market opportunity.

“We are excited for the opportunity to partner with Personalized Biomarkers as they have correctly identified a massive market opportunity, and have formed an exceptional team of industry leaders,” said Shafin Diamond Tejani, Chief Executive Officer of Victory Square. “This is another investment that is fully aligned with our newly created subsidiary, and one we expect to significantly impact the landscape of personalized medicine.”

A partnership with Insight Diagnostics Inc., also through Victory Square Health, will focus on the development of a personalized diagnostic solution for the improved management and prevention of Type II diabetes.

The company’s investment in V2 Games, a development and publishing studio of high-quality mobile games, is another example of incubating great ideas. V2 Games is well known for its successful launch of PAC-MAN Bounce and Beast Brawlers, two of the company’s releases that are capturing the gaming world by the millions of downloads.

In a move designed to strengthen its presence in film and entertainment, Victory Square has acquired a 40 percent equity stake in United Film Fund II, LLC, which is producing three major motion pictures in 2017 and 2018 including “What They Had,” starring two-time Academy Award winner Hilary Swank.

“This kind of investment in entertainment and film represents a major plank for our Company going forward and we consider ourselves fortunate to have the opportunity to acquire this 40% stake in the Film Fund,” said Tejani, who has launched more than 40 startups in 21 countries that employ hundreds of people and generate more than $100 million in annual revenues. “We believe it’s another strong initiative in film production for us and our stakeholders,” he added.

Victory Square has strategically positioned itself in the legal cannabis industry through an investment in Tantalus Labs, a Canadian-based cannabis cultivation company. Tantalus Labs optimizes plant health and sustainable cultivation by using a unique, environmentally controlled greenhouse engineered specifically for growing cannabis. Called a “SunLab,” the greenhouse takes 90 percent less electricity, uses filtered rainwater, and cools the growing environment to prevent stagnant moisture, recycling the air every 7 minutes to achieve maximum airflow.

Victory Square and its leadership team have seamlessly transitioned from its former identity as Fantasy 6 Sports Inc, a company focused solely on fantasy sports, mobile gaming and immersive sports, to a strategic technology company that creates, funds and successfully executes leading-edge ideas. A long-time technology entrepreneur and advocate of the industry, Tejani received the Person-of-the-Year Award at the 2017 Technology Impact Awards in British Columbia, a hallmark award category that recognizes betterment of the tech industry through leadership and philanthropic or enterprise skills and talents. Tejani has pledged to match up to $1 million in donated funds to be shared by a number of Canadian endeavors aimed at education and child-safe projects.

“These are exciting and important steps in the evolution and growth of our Company, and which properly and fully align with our strategic plan focusing on our core competencies in Blockchain Technology, Artificial Intelligence, Gaming, Personalized Health, Film and Virtual, Augmented and Mixed Reality,” said Tejani. “We’re spurred on by the success we have had in building on our original forays into fantasy sports, mobile gaming and immersive sports. In addition, we are energized by our most recent initiatives in sports, personalized health and entertainment and the confidence being shown by our shareholders in the dynamic direction of the Company.”

Victory Square Technologies and its management team believe innovation, incubation of excellent ideas and social responsibility are at the core of its growing success.

Victory Square Technologies Inc. (VSQTF), closed Tuesday's trading session at $1.35, off by 3.70%, on 26,044 volume with 58 trades. The average volume for the last 60 days is 45,203 and the stock's 52-week low/high is $0.298/$3.32.

Recent News

chart

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)

The QualityStocks Daily Newsletter would like to spotlight PreveCeutical Medical Inc. (PRVCF).

CannabisNewsAudio announces the Audio Press Release (APR) titled "Cannabis Continues to Provide Progress in Medical Sector," featuring PreveCeutical Medical Inc. (OTCQB: PRVCF) (CSE: PREV) (FSE: 18H). To hear the NetworkNewsAudio version, visit http://nnw.fm/7f5gT. To read the original editorial, visit http://nnw.fm/8ORpf.

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word “PreveCeutical” – a combination of the words “preventive” and “pharmaceutical” – was a precursor to the company’s formation and incorporation in October 2015.

The company’s first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical’s research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical’s science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland’s (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.’s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company’s core.

PreveCeutical Medical Inc. (PRVCF), closed Tuesday's trading session at $0.2715, off by 7.34%, on 12,000 volume with 9 trades. The average volume for the last 60 days is 23,882 and the stock's 52-week low/high is $0.01/$0.80.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.